PCI Biotech interim Q1 2023 results
Oslo (Norway), 12 May 2023 – PCI Biotech (OSE: PCIB), today announces its interim Q1 2023 results. Please find enclosed the report and presentation.
Highlights review
fimaNAc – bioprocessing
The bioprocessing program for use of fimaNAc in gene therapy manufacturing has generated new results that add to the initial patent application filed in 2H 2022. Upcoming work will focus on generating results that can trigger testing with potential customers to get feedback and develop a competitive technology.
fimaNAc – dermatology
The run-in phase of the dermatology project to demonstrate topical fimaNAc -mediated nucleic acid delivery in a preclinical wound model is ongoing. Readout is expected to be reported in the Q2 2023 interim report. Positive results will be utilised for seeking co-development with partners having therapeutic nucleic acid-based candidates.
fimaVacc – intratumoural immunotherapy
For fimaVacc we are exploring approaches aimed at identifying novel immunotherapy treatment combinations, and a patent application for an undisclosed treatment approach was filed in Q1 2023.
Corporate
The cash position of NOK 51 million enables a financial runway towards the end of 2024 with current plans.
***
A live webcast in Norwegian will be held today, Friday 12 May 2023, at 08:30am – 09:30am CEST (local time).
The presentation can be followed as a live webcast, accessed through the link or the company’s website under “Investors – Reports and presentations – Webcasts”.
There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console.
The interim report and the presentation will also be available on and on the company's webpage, from 07:00am (CEST) today.
For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email:
Mobile:
About PCI Biotech
PCI Biotech is a biopharmaceutical company focussing on development and commercialisation of novel therapies and new technologies through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.
The fimaNAc programme utilises the proven capability of the PCI technology for intracellular delivery of nucleic acids. The technology can be used for most types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids to viral vectors. The development of the fimaNAc programme is currently focussed on selected applications within dermatology and bioprocessing, well suited to the specific strengths of the PCI technology. The fimaVacc programme aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. For further information, please visit:
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Attachments
